Our History

For more than 40 years, Almac has  supported the global Biopharmaceutical industry with their drug development activities and bringing new drugs to market to advance human health.

Sir Allen McClay formed Almac in 2002 born out of Galen Holdings Plc which he founded as Galen Ltd in 1968. Since then the Group has continued to grow organically and employs over 4,000 employees worldwide. Our unrivalled range of services, innovative approach and proven quality record makes Almac a major player in drug development both now and for generations to come.

 

1968

Galen founded by Allen McClay

Galen Ltd was founded by Allen McClay who was inspired by the Greco-Roman doctor and father of modern medicine Claudius Galenus and his philosophy of experience through zealous research.

1978

Pharmaceutical Manufacturing commences in Craigavon, Northern Ireland

1988

Clinical Trial Supply operations commence in Craigavon

1996

Expansion

  • API Manufacturing and Chemical Development services established in Craigavon
  • Expansion to the US with Clinical Trial Supply operations commencing in Audubon, PA, USA

1997

Galen Ltd floats on the stock market to become Galen Holdings Plc – Northern Ireland’s first £ billion company

1999

Purchase of ICTI later to  become Clinical Technologies, Princeton, NJ, USA

2000

Acquisitions

  • Clinical Trial Supply business acquired from Duke University in Durham, NC, USA
  • Galen Holdings announces the acquisition of US company Warner Chilcott and restructures into two separate units – Galen Pharma and Galen Services

2001

On Friday 28th September 2001, Dr Allen McClay OBE, CBE announced his retirement from Galen Holdings

2002

The Almac Group was founded

The Almac Group was founded by Dr Allen McClay and Galen Holdings PLC announced that it had agreed to sell its API Manufacturing and Chemical Development, Clinical Trial Supply and Clinical Technologies businesses to Almac

2003

Global Headquarters open in Craigavon

  • Almac opens its Global Headquarters in Craigavon
  • Almac acquires its Biomarker Discovery & Development business and relocates it within its Craigavon campus.
  • Almac announces the acquisition of Pharmaceutical Manufacturing operations from Galen Holdings Plc

2004

Acquisitions and purchases

  • Almac acquires Peptide & Protein research facility in Elvingston, Scotland
  • Dr Allen McClay announces the purchase of Galen Ltd, the UK based Ethical Pharmaceutical Products Sales and Marketing business

2005

Opening of dedicated facilities for GMP formulation development and biomarker discovery & development services

2006

Dr. Allen McClay, CBE, becomes Sir Allen McClay when Prince Charles knights him at Buckingham Palace

2008

Investments and Discovery

  • Almac invests $120M in its new North American Headquarters (NAHQ)
  • Creation of Almac Discovery, an independent company focussed exclusively on the discovery and development of novel and innovative approaches to the treatment of cancer.

2010

On 12 January, just months before the NAHQ is completed, Sir Allen McClay passes away – However, his vision lives on through his work and the commitment of the Almac Group and family

2011

On 18 May, Senator George Mitchell officially opened Almac’s new North American Headquarter facility in Souderton, PA

2013

New Facilities

  • Opening of dedicated facility for Non-GMP formulation development.
  • Opening of Commercial Packaging facility in Audubon, PA.

2014

Expansion into Asia

  • Expands Asia pacific operations
  • Establishes regional operations center in Singapore

2015

Acquisitions

  • Announced the acquisition of 100% shares of Arran Chemical Company and expands Biocatalysis services.
  • Almac confirmed a £16 million investment to expand its formulation and analytical development services to meet ongoing client demand – operating a significant proportion of the 70-acre Charnwood Campus in Loughborough, England

2016

Opening of new companion diagnostic development facility located in the Research Triangle Park region of North Carolina, USA.